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Elevated non-high density lipoprotein cholesterol (non-HDL-C) was the commonest lipid
abnormality among T2DM patients with cardiovascular events (CV) events. Prevalence of
elevated non-HDL-C was 21.6% among patients who were on statin therapy and with
optimal low density lipoprotein-cholesterol (LDL-C) levels. Despite an optimal LDL-C level,
47% of the T2DM patients with CV events had elevated non-HDL-C.
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journal homepage: www.elsevier.com/locate/ihjDiabetes is a common secondary cause of hyperlipidemia,
particularly if glycemic control is poor. Indians are genetically
predisposed to the development of coronary heart disease (CHD)
due to dyslipidemia and low levels of high density lipoproteins.1
Recently, it has been found that non-high density lipoprotein
cholesterol (non-HDL-C) has a distinct advantage over low
density lipoprotein-cholesterol (LDL-C) in predicting CHD.2,3
Perhaps there is paucity of data on non-HDL-C from Indian
population and not much attention has been paid to use of non-
HDL-C for routine clinical practice in India. Hence, the present
study was aimed to assess the non-HDL-C level among patients
with T2DM and to determine the various lipid abnormalities
including elevated non-HDL-C among T2DM patients who had a
history of cardiovascular events.
A hospital-based, observational study was conducted
among 808 patients with T2DM, who attended a tertiary care
hospital for DM during the study period of October 2014 to
March 2015. The study population included all patients aged
between 30 and 65 years with duration of diabetes more than
ﬁve years and were screened for laboratory investigations and
medications. Patients with T1DM and gestational diabetes
were excluded. The patient history related to cardiovascular
events was also recorded. The study was approved by the
ethics committee of the institution.
The most common lipid abnormalities were low HDL-C
(65%) followed by elevated non-HDL-C (43%). Out of 808patients, only 58 patients had a previous history of
cardiovascular events (CV) events. Among the patients with
CV events, 73% had optimal LDL-C. Despite this, 47% of the
patients had elevated non-HDL-C. An elevated non-HDL-C
was the commonest lipid abnormality among those with CV
events and more than 77% had poor glycemic control. Of the
total study population, 67.1% of them were on statin
therapy. The prevalence of elevated non-HDL-C was 21.6%
among patients who were on statin therapy and with
optimal LDL-C levels.
In the present study, nearly 47% had elevated non-HDL-C
among patients with a history of cardiovascular event (Table 1).
This indicates that many patients with type 2 diabetes fail to
reach goals for non-HDL-C. They meet their target LDL-C goal
but still develop complications from atherosclerotic vascular
disease and suffer from cardiovascular events. One of the main
limitations of this study was that it is not an intervention study
to conﬁrm the superiority of non-HDL-C over LDL-C. Further
studies on non-HDL-C must be undertaken in future to
recommend non-HDL-C as the primary target for patients
with type 2 diabetes.
In conclusion, the study highlights that there are lipid
abnormalities like lower HDL-C and higher non-HDL-C levels
among patients with type 2 diabetes with CV events. Despite
an optimal LDL-C level, 47% of the patients with CV events had
an elevated non-HDL-C adding to the residual risk of CV
Table 1 – Prevalence of lipid abnormalities and glycemic status among patients who had history of CV events (n = 58) (7.2%).
Glycemic status Lipid abnormalities
HbA1C ≥ 7% "TC (mg/dL) "LDL-C (mg/dL) #HDL-C (mg/dL) "TG (mg/dL) "Non-HDL-C (mg/dL)
45 (77.6%)* 11 (19%) 16 (27.6%) 23 (39.7%) 13 (22.4%) 27 (47.6%)
* Values are n (%).
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 3 7 8 – 3 7 9 379events. Thus, it is recommended that non-HDL-C should be
included in the routine lipid assessment of patients with type 2
diabetes.
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